Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$864.04M
• Dividend Yield: 2.5%
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): 95.5
• Beta (1Y): 0.03
• Revenue Growth: 7.83%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 372,429,530
• 10 Day Avg. Volume: 1,010,272
• 30 Day Avg. Volume: 1,258,553
• PEG Ratio: 1.02
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 27.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.55
• Price Target Upside: 53.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 51 Neutral
• Price Target: AU$2.50 ▲(7.76%Upside)

The overall stock score of 51 reflects significant financial performance challenges, particularly in profitability and leverage, despite strong revenue growth. While technical analysis shows a neutral stance, the high P/E ratio indicates overvaluation concerns, impacting the stock's appeal.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Ltd. (IDX) is a leading provider of medical imaging services in Australia and New Zealand. It operates through a network of diagnostic imaging clinics that offer a comprehensive range of services, including X-rays, CT scans, MRIs, ultrasounds, and nuclear medicine. The company is committed to delivering high-quality, patient-centered care with advanced technology and a team of highly skilled radiologists and healthcare professionals.

How the Company Makes Money

Integral Diagnostics Ltd. generates revenue primarily through the provision of diagnostic imaging services. The company's key revenue streams include fees charged for imaging procedures such as X-rays, MRIs, CT scans, and other radiology services. These services are offered to patients directly, as well as through partnerships with healthcare providers, hospitals, and medical practitioners who refer their patients for imaging diagnostics. Additionally, IDX may have agreements with health insurance providers, which reimburse the company for services provided to insured patients. The company's earnings are further supported by its strategic location of clinics in populous areas, ensuring a steady flow of patients, and by leveraging cutting-edge imaging technology to provide efficient and accurate diagnostics.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. demonstrates robust revenue growth and efficient cash management. However, significant challenges are evident in profitability, as seen in negative net income and deteriorating EBIT margins. The high leverage and negative return on equity indicate financial risks. While operational cash flow remains strong, the overall financial health is mixed, with strengths in revenue growth and cash management but weaknesses in profitability and leverage.

Income Statement

The company shows mixed results in its income statement. Gross profit margin is high at 95.12%, indicating effective cost management relative to revenue. However, the net profit margin is negative due to a net loss, which is a significant concern. Revenue growth is strong at 6.72% year-over-year, demonstrating a positive trend in sales. However, EBIT and EBITDA margins have declined sharply, reflecting operational challenges.

Balance Sheet

The balance sheet presents a stable financial position with an equity ratio of 40.54%, indicating a solid equity base. However, the debt-to-equity ratio is high at 1.19, pointing to significant leverage that could pose risks in challenging economic conditions. Return on Equity has turned negative due to the net loss, highlighting profitability issues.

Cash Flow

The cash flow statement reveals steady operational cash flows with an operating cash flow to net income ratio of -1.09, indicating strong cash generation relative to net income despite losses. Free cash flow growth is significant at 54.21%, showcasing effective cash management, but free cash flow to net income ratio is negative, underscoring profitability concerns.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
491.32M	469.70M	440.10M	358.74M	348.81M	274.08M
	Gross Profit
130.74M	446.78M	97.76M	83.84M	92.19M	72.06M
	EBIT
77.58M	42.17M	40.14M	38.45M	47.87M	38.40M
	EBITDA
78.95M	12.33M	92.74M	69.90M	88.94M	69.50M
	Net Income Common Stockholders
5.66M	-60.70M	25.04M	14.60M	31.27M	23.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
17.99M	42.44M	33.85M	123.19M	62.20M	57.97M
	Total Assets
745.80M	744.28M	839.01M	783.01M	654.90M	586.91M
	Total Debt
361.49M	357.80M	365.08M	340.99M	308.36M	277.85M
	Net Debt
343.50M	315.36M	331.22M	217.80M	246.15M	219.88M
	Total Liabilities
445.42M	442.57M	465.96M	435.77M	400.16M	358.58M
	Stockholders Equity
300.38M	301.71M	373.05M	347.24M	254.74M	228.33M
Cash Flow		Free Cash Flow
34.15M	42.28M	27.42M	9.33M	49.30M	28.37M
	Operating Cash Flow
73.12M	66.16M	71.42M	37.10M	69.57M	54.25M
	Investing Cash Flow
-44.45M	-27.90M	-128.96M	-55.69M	-56.66M	-93.53M
	Financing Cash Flow
-14.87M	-29.45M	-31.85M	81.13M	-7.83M	75.40M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Negative. The current price of 2.32 is below the 20-day moving average (MA) of 2.44, below the 50-day MA of 2.36, and below the 200-day MA of 2.69, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.32 is Neutral, neither overbought nor oversold. The STOCH value of 14.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANZ	74 Outperform	$87.53B	13.00	9.75%	5.66%	20.95%	-7.97%
SHL	72 Outperform	AU$12.68B	23.17	6.86%	4.05%	10.15%	6.20%
RHC	66 Neutral	AU$8.65B	1,057.58	0.52%	2.23%	7.25%	-99.04%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
IDX	51 Neutral	AU$864.04M	95.47	1.14%	2.50%	7.83%	―
HLS	45 Neutral	€602.69M	―	-4.46%	―	-7.82%	98.08%
MVP	44 Neutral	AU$69.85M	―	-45.40%	―	13.61%	-55.12%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics CEO Announces Retirement, Initiates Leadership Transition

Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Present at 2025 Macquarie Australia Conference

Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics

Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.

Integral Diagnostics Announces Change of Registered Office

Integral Diagnostics Ltd. has announced a change in its registered office and principal place of business to a new location in East Melbourne, effective 17 April 2025. This change reflects the company’s ongoing commitment to maintaining efficient operations and potentially enhancing its service delivery capabilities.

Integral Diagnostics Announces Cessation of Securities

Integral Diagnostics Ltd. announced the cessation of certain securities, specifically 50,871 performance rights under LTI and 10,101 under STI, due to unmet conditions. This cessation may impact the company’s financial structuring and stakeholder interests, reflecting on the company’s operational strategies and market positioning.

Integral Diagnostics Director Increases Shareholding

Integral Diagnostics Ltd. announced a change in the director’s interest, with James Tobias Hall acquiring an additional 2,088 fully paid ordinary shares through the company’s Dividend Reinvestment Plan. This acquisition reflects a modest increase in the director’s holdings, potentially signaling confidence in the company’s future performance and aligning with shareholder interests.

Integral Diagnostics Announces Quotation of New Securities

Integral Diagnostics Ltd. has announced the application for quotation of 610,566 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and offering opportunities for stakeholders to engage with the company’s growth strategy.

Integral Diagnostics Updates Dividend Distribution Details

Integral Diagnostics Ltd. has updated its previous announcement regarding the dividend distribution for the period ending December 31, 2024. The update includes details on the exchange rate for converting the Australian Dollar denominated dividend into New Zealand dollars and the Dividend Reinvestment Plan (DRP) share price. This announcement is significant for shareholders as it provides clarity on the financial aspects of their investments and reflects the company’s commitment to transparent communication with its stakeholders.

Vanguard Group Acquires Substantial Stake in Integral Diagnostics

The Vanguard Group has become a substantial holder in Integral Diagnostics Ltd., acquiring a 5.124% voting power with 19,051,852 ordinary shares. This acquisition signifies a significant investment by Vanguard, potentially impacting Integral Diagnostics’ market position and indicating confidence in the company’s future prospects.

Integral Diagnostics Director Increases Shareholding

Integral Diagnostics Ltd. announced a change in the director’s interest, with Raelene Murphy acquiring an additional 15,000 fully paid ordinary shares, bringing her total to 45,945 shares. This transaction, conducted through an on-market trade at $2.36 per share, reflects a strategic move that could influence the company’s governance and stakeholder confidence.